These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 37435300)

  • 21. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empowering Muscle Stem Cells for the Treatment of Duchenne Muscular Dystrophy.
    Filippelli RL; Chang NC
    Cells Tissues Organs; 2022; 211(6):641-654. PubMed ID: 33910206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From diagnosis to therapy in Duchenne muscular dystrophy.
    Babbs A; Chatzopoulou M; Edwards B; Squire SE; Wilkinson IVL; Wynne GM; Russell AJ; Davies KE
    Biochem Soc Trans; 2020 Jun; 48(3):813-821. PubMed ID: 32597486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
    Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
    Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular therapy for Duchenne muscular dystrophy (DMD).
    Thapa S; Elhadidy S; Asakura A
    Fac Rev; 2023; 12():3. PubMed ID: 36873982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
    Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting fibrosis in Duchenne muscular dystrophy.
    Zhou L; Lu H
    J Neuropathol Exp Neurol; 2010 Aug; 69(8):771-6. PubMed ID: 20613637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.
    McGreevy JW; Hakim CH; McIntosh MA; Duan D
    Dis Model Mech; 2015 Mar; 8(3):195-213. PubMed ID: 25740330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review.
    Chung Liang L; Sulaiman N; Yazid MD
    Front Bioeng Biotechnol; 2022; 10():833833. PubMed ID: 35402409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The golden retriever model of Duchenne muscular dystrophy.
    Kornegay JN
    Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
    Péladeau C; Jasmin BJ
    Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy.
    Townsend D; Yasuda S; Chamberlain J; Metzger JM
    Trends Cardiovasc Med; 2009 Feb; 19(2):50-55. PubMed ID: 19577712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
    Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
    Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies.
    Mareedu S; Million ED; Duan D; Babu GJ
    Front Physiol; 2021; 12():647010. PubMed ID: 33897454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic correction strategies for Duchenne Muscular Dystrophy and their impact on the heart.
    Johnston JR; McNally EM
    Prog Pediatr Cardiol; 2021 Dec; 63():. PubMed ID: 34898968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy.
    Naidoo M; Anthony K
    Mol Neurobiol; 2020 Mar; 57(3):1748-1767. PubMed ID: 31836945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene Therapy for Duchenne Muscular Dystrophy.
    Elangkovan N; Dickson G
    J Neuromuscul Dis; 2021; 8(s2):S303-S316. PubMed ID: 34511510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay JP
    Front Med (Lausanne); 2022; 9():859930. PubMed ID: 35419381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.